Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
Capecitabine
DPYD genotyping
DPYD*2A
Fluoropyrimidines toxicity
Fluorouracil
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
07
08
2020
accepted:
20
11
2020
pubmed:
5
12
2020
medline:
22
6
2021
entrez:
4
12
2020
Statut:
ppublish
Résumé
Fluoropyrimidines are used in chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. DPYD*2A polymorphism is one of the most studied variants. The study objective was to document the impact of implementing this test in routine clinical practice. We retrospectively performed chart reviews of all patients who tested positive for a heterozygous or homozygous DPYD*2A mutation in samples obtained from patients throughout the province of Quebec, Canada. During a period of 17 months, 2,617 patients were tested: 25 patients tested positive. All were White. Twenty-four of the 25 patients were heterozygous (0.92%), and one was homozygous (0.038%). Data were available for 20 patients: 15 were tested upfront, whereas five were identified after severe toxicities. Of the five patients confirmed after toxicities, all had grade 4 cytopenias, 80% grade ≥3 mucositis, 20% grade 3 rash, and 20% grade 3 diarrhea. Eight patients identified with DPYD*2A mutation prior to treatment received fluoropyrimidine-based chemotherapy at reduced initial doses. The average fluoropyrimidine dose intensity during chemotherapy was 50%. No grade ≥3 toxicities were observed. DPYD*2A test results were available in an average of 6 days, causing no significant delays in treatment initiation. Upfront genotyping before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. The administration of chemotherapy at reduced doses appears to be safe in patients heterozygous for DPYD*2A. Fluoropyrimidines are part of chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. This retrospective analysis demonstrates that upfront genotyping of DPYD before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. This approach was reported previously, but insufficient data concerning its application in real practice are available. This is likely the first reported experience of systematic DPYD genotyping all over Canada and North America as well.
Sections du résumé
BACKGROUND
Fluoropyrimidines are used in chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. DPYD*2A polymorphism is one of the most studied variants. The study objective was to document the impact of implementing this test in routine clinical practice.
METHODS
We retrospectively performed chart reviews of all patients who tested positive for a heterozygous or homozygous DPYD*2A mutation in samples obtained from patients throughout the province of Quebec, Canada.
RESULTS
During a period of 17 months, 2,617 patients were tested: 25 patients tested positive. All were White. Twenty-four of the 25 patients were heterozygous (0.92%), and one was homozygous (0.038%). Data were available for 20 patients: 15 were tested upfront, whereas five were identified after severe toxicities. Of the five patients confirmed after toxicities, all had grade 4 cytopenias, 80% grade ≥3 mucositis, 20% grade 3 rash, and 20% grade 3 diarrhea. Eight patients identified with DPYD*2A mutation prior to treatment received fluoropyrimidine-based chemotherapy at reduced initial doses. The average fluoropyrimidine dose intensity during chemotherapy was 50%. No grade ≥3 toxicities were observed. DPYD*2A test results were available in an average of 6 days, causing no significant delays in treatment initiation.
CONCLUSION
Upfront genotyping before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. The administration of chemotherapy at reduced doses appears to be safe in patients heterozygous for DPYD*2A.
IMPLICATIONS FOR PRACTICE
Fluoropyrimidines are part of chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. This retrospective analysis demonstrates that upfront genotyping of DPYD before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. This approach was reported previously, but insufficient data concerning its application in real practice are available. This is likely the first reported experience of systematic DPYD genotyping all over Canada and North America as well.
Identifiants
pubmed: 33274825
doi: 10.1002/onco.13626
pmc: PMC8018309
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Capecitabine
6804DJ8Z9U
Dihydrouracil Dehydrogenase (NADP)
EC 1.3.1.2
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e597-e602Informations de copyright
© 2020 AlphaMed Press.
Références
Pharmacotherapy. 2020 Nov;40(11):1108-1129
pubmed: 32985005
J Clin Oncol. 2016 Jan 20;34(3):227-34
pubmed: 26573078
Int J Cancer. 2015 Dec 15;137(12):2971-80
pubmed: 26099996
Br J Cancer. 2017 May 23;116(11):1415-1424
pubmed: 28427087
Mol Cancer Ther. 2006 Nov;5(11):2895-904
pubmed: 17121937
J Natl Cancer Inst. 2014 Nov 07;106(12):
pubmed: 25381393
Lancet Oncol. 2015 Dec;16(16):1639-50
pubmed: 26603945
Lancet Oncol. 2018 Nov;19(11):1459-1467
pubmed: 30348537
J Clin Oncol. 2001 Nov 1;19(21):4097-106
pubmed: 11689577
Eur J Cancer. 2019 Jan;107:60-67
pubmed: 30544060
JAMA Oncol. 2016 May 1;2(5):655-662
pubmed: 26794347
J Clin Oncol. 2008 May 1;26(13):2131-8
pubmed: 18299612
Bull Cancer. 2018 Apr;105(4):397-407
pubmed: 29486921
Pharmacogenomics. 2013 Aug;14(11):1255-72
pubmed: 23930673
J Clin Oncol. 2004 Aug 15;22(16):3408-19
pubmed: 15199089
Clin Cancer Res. 2001 May;7(5):1149-53
pubmed: 11350878
Ann Oncol. 2017 Dec 1;28(12):2915-2922
pubmed: 29045513
Clin Pharmacokinet. 2006;45(6):567-92
pubmed: 16719540
J Clin Oncol. 1998 Sep;16(9):2943-52
pubmed: 9738562
Ann Oncol. 1996 Nov;7(9):961-5
pubmed: 9006748
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Ann Pharmacother. 2001 Feb;35(2):217-27
pubmed: 11215843
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959